|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for STRA13 |
 Gene summary |
| Basic gene Info. | Gene symbol | STRA13 |
| Gene name | stimulated by retinoic acid 13 | |
| Synonyms | CENP-X|CENPX|D9|FAAP10|MHF2 | |
| Cytomap | UCSC genome browser: 17q25.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001271006.1, NM_001271007.1,NM_144998.3, | |
| Description | FANCM-interacting histone fold protein 2Fanconi anemia-associated polypeptide of 10 kDacentromere protein Xretinoic acid-inducible gene D9 protein homologstimulated by retinoic acid 13 homologstimulated by retinoic acid gene 13 protein homolog | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 615128 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000169689 | ||
| HPRD : 18121 | ||
| Vega : OTTHUMG00000132129 | ||
| Protein | UniProt: A8MT69 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_STRA13 | |
| BioGPS: 201254 | ||
| Pathway | NCI Pathway Interaction Database: STRA13 | |
| KEGG: STRA13 | ||
| REACTOME: STRA13 | ||
| Pathway Commons: STRA13 | ||
| Context | iHOP: STRA13 | |
| ligand binding site mutation search in PubMed: STRA13 | ||
| UCL Cancer Institute: STRA13 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for STRA13 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | E13 | L14R | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for STRA13 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | E13 | L14R | -1.3010401 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for STRA13 from PDB |
| Top |
| Differential gene expression and gene-gene network for STRA13 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for STRA13 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for STRA13 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of STRA13 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | NUC | Nucleic Acids | 4ndy | M | E13 | NUC | Nucleic Acids | 4ndy | V | E13 | NUC | Nucleic Acids | 4ne1 | p | E13 |
| Top |
| Conservation information for LBS of STRA13 |
| Multiple alignments for A8MT69 in multiple species |
| LBS | AA sequence | # species | Species | D80 | PQLLLDF | 3 | Homo sapiens, Bos taurus, Mus musculus | E13 | SGFRKELVSRL | 2 | Homo sapiens, Mus musculus | E13 | AVFRKELVSKL | 1 | Bos taurus | G32 | KTKVSGDALQL | 3 | Homo sapiens, Bos taurus, Mus musculus | H20 | VSRLLHLHFKD | 1 | Homo sapiens | H20 | VSKLLHLHFKD | 1 | Bos taurus | H20 | VSRLLHLHFRD | 1 | Mus musculus | K29 | KDDKTKVSGDA | 1 | Homo sapiens | K29 | KDKKTKVSGDA | 1 | Bos taurus | K29 | RDCKTKVSGDA | 1 | Mus musculus | Q76 | EKVLPQLLLDF | 3 | Homo sapiens, Bos taurus, Mus musculus | R17 | KELVSRLLHLH | 2 | Homo sapiens, Mus musculus | R17 | KELVSKLLHLH | 1 | Bos taurus | S16 | RKELVSRLLHL | 2 | Homo sapiens, Mus musculus | S16 | RKELVSKLLHL | 1 | Bos taurus | S31 | DKTKVSGDALQ | 1 | Homo sapiens | S31 | KKTKVSGDALQ | 1 | Bos taurus | S31 | CKTKVSGDALQ | 1 | Mus musculus | T28 | FKDDKTKVSGD | 1 | Homo sapiens | T28 | FKDKKTKVSGD | 1 | Bos taurus | T28 | FRDCKTKVSGD | 1 | Mus musculus | V30 | DDKTKVSGDAL | 1 | Homo sapiens | V30 | DKKTKVSGDAL | 1 | Bos taurus | V30 | DCKTKVSGDAL | 1 | Mus musculus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |